Clinical Quiz: Impact of New MASLD Nomenclature on 2023 AASLD NAFLD Guidance

In 2023, a multisociety Delphi process yielded updated nomenclature for what was then known as nonalcoholic fatty liver disease (NAFLD), a common liver disease estimated to affect up to 25% of US adults and 30% of the total global population.

Recognizing the stigmatizing nature of the terminology and fundamental inaccuracies related to the natural history of the disease, multiple global hepatology and gastroenterology societies, patients and patient advocacy organizations, regulatory experts, and industry representatives set out to rectify these issues with the implementation of revised metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature.

Earlier in 2023, the American Association for the Study of Liver Diseases (AASLD) published Practice Guidance on the Clinical Assessment and Management of NAFLD. In a later commentary intended to serve as an accompanying article to this guidance, AASLD sought to clarify its clinical application in the context of the new nomenclature.

Test your knowledge of the 2023 AASLD NAFLD Practice Guidance and the implications of the new MASLD nomenclature with this clinical quiz!

References

1. Brooks, A. From NAFLD to MASLD: 2023 Brings New Liver Disease Nomenclature. HCPLive. December 13, 2024. Accessed November 26, 2024. https://www.hcplive.com/view/from-nafld-to-masld-2023-new-liver-disease-nomenclature
2. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. doi:10.1097/HEP.0000000000000323
3. Kanwal F, Neuschwander-Tetri BA, Loomba R, et al. Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. doi:10.1097/HEP.0000000000000670